Abstract
Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Drug Delivery Letters
Title:Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles
Volume: 8 Issue: 3
Author(s): Zahrah Alhalili, Joe Shapter*, Daniela Figueroa and Barbara Sanderson
Affiliation:
- Flinders Centre for NanoScale Science and Technology, School of Chemical and Physical Sciences, Flinders University, Adelaide, SA 5001,Australia
Keywords: Gold nanoparticles, paclitaxel, EpCAM, TARP, antibodies, cytotoxicity, drug delivery.
Abstract: Background and Objective: Gold nanoparticles (AuNP) conjugated with either EpCAM or TARP antibodies and an anticancer agent, paclitaxel (PTX), for tumour targeting and therapy were synthesised using a simple chemistry.
Methods: The AuNP surface was functionalised using a two-step modification approach. The conjugates were characterised using Transmission Electron Microscopy (TEM) and infrared spectroscopy.
Results: The cytotoxicity assay of T47D cells treated with only antibodies conjugated to the gold nanoparticles did not show any cytotoxicity to the cells, which indicates these nanoconjugates are suitable for intracellular delivery of anticancer drugs.
Conclusion: When using AuNPs with antibodies and the cancer chemotherapy agent PTX attached simultaneously to the functionalised AuNPs, the reduction of cell viability was significantly higher compared to PTX-thiol-AuNPs conjugate system where no antibodies were used.
Export Options
About this article
Cite this article as:
Alhalili Zahrah, Shapter Joe*, Figueroa Daniela and Sanderson Barbara, Specific Targeting of Breast Cancer Cells with Antibodies Conjugated Gold Nanoparticles, Drug Delivery Letters 2018; 8 (3) . https://dx.doi.org/10.2174/2210303108666180913115509
DOI https://dx.doi.org/10.2174/2210303108666180913115509 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polymorphisms in TOLL-Like Receptor Genes and their Roles in Allergic Asthma and Atopy
Recent Patents on Inflammation & Allergy Drug Discovery Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Overcoming Endocrine Resistance in Breast Cancer
Current Cancer Drug Targets Crosstalk Between Bioactive Peptide and Intestinal Barrier in Gut Homeostasis
Current Protein & Peptide Science KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence
Current Cancer Drug Targets Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Breast Cancer Detection and Classification using Traditional Computer Vision Techniques: A Comprehensive Review
Current Medical Imaging Comparative Genomic Hybridization: A Valuable Tool for Genome-Scale Analysis of Rodent Cancer Models
Current Genomics Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Endocannabinoids: A New Family of Lipid Mediators Involved in the Regulation of Neural Cell Development
Current Pharmaceutical Design Characterization of YY1 OPB Peptide for its Anticancer Activity
Current Cancer Drug Targets Modulation of Mitochondrial and Epigenetic Targets by Polyphenols-rich Extract from Araucaria angustifolia in Larynx Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Ulcerative Colitis: A Cinderella Story (Guest Editor: Silvio Danese)]
Current Drug Targets Editorial (Thematic Issue: Combined Cancer Therapy)
Current Pharmaceutical Design In Vivo Pharmacokinetics, Immunogenicity and Mechanism of PEGylated Antitumor Polypeptide
Current Pharmaceutical Design Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Inhibitory Effect of Fruit Juices on the Doxorubicin Metabolizing Activity of Carbonyl Reductase 1
Drug Metabolism Letters Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy ProBDNF is a Novel Mediator of the Interaction Between MDA-MB- 231 Breast Cancer Cells and Brain Microvascular Endothelial Cells
Current Molecular Medicine